logo-loader

Silence Therapeutics team discuss major multi-target deal with AstraZeneca

Published: 12:28 27 Mar 2020 GMT

Silence Therapeutics (LON:SLN) chief financial officer Rob Quinn and head of business development John Strafford discuss this week's 'transformational' deal they've struck with major AstraZeneca.

It's worth US$80mln in cash and investment upfront, plus a further US$400mln in milestone payments and royalties for each disease area targeted.

Using Silence’s small interfering RNA, or siRNA technology, AstraZeneca is looking to initially develop treatments for liver, heart and lung diseases.

FTSE starts flat, Unilever jumps on ice cream overhaul - Market Report

The FTSE 100 has opened flat, with the largest gain coming from multinational consumer goods heavyweight Unilever. The company lifted more than 5% in early trading after launching plans to sack 7,500 workers as part of an overhaul of its ice cream business. Over in the pharmaceutical...

2 hours, 23 minutes ago